Company intelligence / Profile preview
Polymed Biopharmaceuticals
Hangzhou, Zhejiang, Chinapolymedbiopharma.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
Polymed has developed a pipeline of novel bifunctional degraders targeting previously "undruggable" proteins. Their lead asset HPB-143 (an IRAK4 degrader) reached IND clearance with the FDA and was outlicensed to Photys Therapeutics for global development outside Greater China/Southeast Asia. The company also disclosed new FLT3/IRAK4 inhibitors for cancer and autoimmune indications. Clinical data on efficacy/safety are not yet public as of May 2025.
- Therapeutic areas
- OncologyCardiovascularImmunologyNeurology
- Modalities
- PROTACs (Proteolysis Targeting Chimeras)Degrader Antibody Conjugates (DACs)small moleculesantibody-drug conjugates
- Industry
- Biotech
02
Drug pipeline
6 assets5 more assets in the full pipeline.
03
Partnerships
Photys Therapeutics—exclusive license agreement for global rights to HPB‑143/PHT‑776 outside Greater China/Southeast Asia
Beyond the preview
Go deeper on Polymed Biopharmaceuticals.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Polymed Biopharmaceuticals.